4basebio
Tracked across 3 events · 19 articles · First seen May 20, 2026 · Last active Aug 26, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: 4basebio signed a Clinical Supply Agreement to provide GMP-grade opDNA for a Phase II clinical trial, securing a seven-figure revenue stream and demonstrating the commercial momentum of its technology.
May 20, 2026 · 6 articles
Business
Impact: 4basebio appointed Jeff Coller to its Strategic Advisory Board, which is expected to enhance its synthetic DNA and mRNA manufacturing capabilities and strategic direction.
Jun 15, 2026 · 6 articles
Business
Impact: 4basebio is the primary beneficiary, as the collaboration expands market access for its hpDNA technology, potentially driving revenue growth and validating its platform.
Aug 26, 2026 · 7 articles
ERGEN INTELLIGENCE
Track 4basebio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard